Health economic evaluation of four prenatal screening strategies for Down syndrome in Changsha, China.
10.3760/cma.j.cn511374-20211030-00864
- Author:
Jun HE
1
;
Shunyao WANG
;
Jingjing ZHANG
;
Shihao ZHOU
;
Yang KUANG
;
Jia DING
;
Mengyue YANG
;
Jiawei LIN
;
Siyi DING
;
Shaolan LIU
;
Huanhuan PENG
;
Nan WANG
;
Jiyang LIU
Author Information
1. Changsha Maternal and Child Health Care Hospital, Changsha, Hunan 410007, China. ncwang@hnu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Child;
China;
Cost-Benefit Analysis;
Down Syndrome/diagnosis*;
Female;
Humans;
Pregnancy;
Prenatal Diagnosis/methods*;
Retrospective Studies
- From:
Chinese Journal of Medical Genetics
2022;39(8):803-808
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the clinical application and health economic values of non-invasive prenatal testing (NIPT) and second trimester serum screening (STSS).
METHODS:A retrospective analysis was carried out on 54 026 singleton pregnant women undergoing NIPT and STSS from March 1, 2018 to December 31, 2019 in Changsha Maternal and Child Health Care Hospital. For pregnant women with high-risk results of NIPT, prenatal diagnosis and follow-up of pregnancy outcomes were conducted. The data was grouped to 4 screening models, and their cost-benefit was analyzed.
RESULTS:The sensitivity, specificity and positive predictive value of NIPT were all higher than STSS. Screening models 1 to 4 have prevented the birth of 71, 29, 52 and 54 patients with Down syndrome, respectively. The safety index of screening models 1 to 4 were 0.0036, 0.3944, 02215 and 0.1281, respectively. When the price of NIPT was decreased to 600 RMB, the cost-benefit of the screening models 1 to 4 was 0.46, 0.65, 0.44 and 0.40 million RMB, respectively.
CONCLUSION:NIPT has a better detection performance than STSS. When the price of NIPT is 600 RMB, screening model 1 has the best screening effect and the highest accuracy, safety index and health economical value.
